Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fusion Antibodies's Other Operating Expense for the
six
months ended in Sep. 2025 was £-0.37 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2025 was £-0.55 Mil.
Fusion Antibodies's quarterly Other Operating Expense
declined
from Sep. 2024 (£0.00 Mil) to Mar. 2025 (£-0.18 Mil) and
declined
from Mar. 2025 (£-0.18 Mil) to Sep. 2025 (£-0.37 Mil).
Fusion Antibodies's annual Other Operating Expense
increased
from Mar. 2023 (£-0.01 Mil) to Mar. 2024 (£-0.00 Mil) and
increased
from Mar. 2024 (£-0.00 Mil) to Mar. 2025 (£0.00 Mil).
Fusion Antibodies Other Operating Expense Related Terms
Fusion Antibodies Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Fusion Antibodies's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of £-0.55 Mil mean?
Fusion Antibodies (LSE:FAB) has a Other Operating Expense of £-0.55 Mil as of Sep. 2025. Other operating expenses that a company records on its income statement. View historical data on Fusion Antibodies and its competitors.
Is Fusion Antibodies' Other Operating Expense too high?
Fusion Antibodies' current Other Operating Expense is £-0.55 Mil. Overall, Fusion Antibodies has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' Other Operating Expense compare to VRTX and REGN?
Fusion Antibodies' Other Operating Expense of £-0.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Fusion Antibodies and its competitors. Fusion Antibodies's current Other Operating Expense is £-0.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.10 — trading 156.3% above its estimated fair value. The current Other Operating Expense is £-0.55 Mil. Fusion Antibodies' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current Other Operating Expense is £-0.55 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?
Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued.
The current stock price of £0.10 is trading 156.3% above its estimated GF Value™ of £0.04.
GuruFocus considers Fusion Antibodies to be Significantly Overvalued.
Key valuation signals for LSE:FAB:
Other Operating Expense: £-0.55 Mil
GF Value™: £0.04 vs. price of £0.10 (156.3% above fair value)
No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
26GF Score
Get the complete analysis for LSE:FAB
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
